News Formal

Ozempic Maker Novo Nordisk Sinks On Disappointing Earnings Amid Booming Demand For Weight Loss And Diabetes Drugs

  • 📰 Forbes
  • ⏱ Reading Time:
  • 20 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 39%
  • Publisher: 53%

Novo Nordisk Nouvelles

Eli Lilly,Weight Loss,Obesity

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Pharma giant Novo Nordisk on Wednesday reported booming demand for its weight loss and diabetes drugs Ozempic and Wegovy, but shares sank after the Danish firm disappointed investors with less-than-expected profits for the second quarter and a slimmed-down profit outlook for the year as it facesNovo Nordisk reported net profit of 20.05 billion Danish kroner in the second quarter of 2024, below consensus analyst estimates but an increase of 3% from the same time last year.

The figure marks an increase of a quarter from the same time period last year, when Novo pulled in $7.9 billion in sales. Overall, Novo said the GLP-1 class made up nearly half of sales in the first quarter, around $5.4 billion, up 33% from the same time last year, and the company raised sales expectations for the full year from 19% to 27% at constant exchange rates to 22% to 28%.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 394. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Novo Nordisk shares dip as Wegovy maker posts earnings miss, cuts operating profit outlookNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
La source: NBCPhiladelphia - 🏆 569. / 51 Lire la suite »

Shares of Wegovy maker Novo Nordisk slide 5% after earnings missNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
La source: NBCNewYork - 🏆 270. / 63 Lire la suite »

Shares of Wegovy maker Novo Nordisk slide 7% after earnings missNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
La source: CNBC - 🏆 12. / 72 Lire la suite »

Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlookNovo Nordisk on Wednesday announced its second quarter earnings for 2024.
La source: NBCLA - 🏆 319. / 59 Lire la suite »